Envirotech Vehicles appoints Jason Maddox to board of directors
In a recent transaction, Bernhardt G. Zeiher, a director at Amylyx Pharmaceuticals , Inc. (NASDAQ:AMLX), acquired 10,000 shares of the company’s common stock. The purchase, completed on March 20, 2025, amounted to a total of $37,005. According to InvestingPro data, this insider buy comes as the stock trades below its Fair Value, with analyst targets ranging from $3 to $12 per share. The shares were bought at a weighted average price of $3.7005 per share, with individual transaction prices ranging from $3.65 to $3.73. This acquisition brings Zeiher’s total holdings in the company to 10,000 shares, reflecting a direct ownership stake. The stock has shown strong momentum with a 33% return over the past year, despite the company’s current FAIR financial health rating. For deeper insights into AMLX’s valuation and growth prospects, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Amylyx Pharmaceuticals has announced that the U.S. Food and Drug Administration has lifted the clinical hold on its Phase 1 trial for AMX0114, a potential treatment for amyotrophic lateral sclerosis (ALS). This decision allows Amylyx to proceed with patient screening, enrollment, and dosing across the United States. The trial, named LUMINA, will evaluate the safety and biological activity of AMX0114 in a randomized, placebo-controlled study involving approximately 48 individuals. Additionally, Amylyx has entered into a collaboration with Gubra A/S to develop a novel long-acting GLP-1 receptor antagonist for diabetes treatment. Under the terms of this agreement, Amylyx will make an upfront payment and Gubra could receive over $50 million in milestone payments. This partnership highlights Amylyx’s strategy to expand its pipeline beyond neurodegenerative diseases and into metabolic disorders. The company maintains its cash runway projection into 2026, despite the financial commitments of the collaboration. These developments underscore Amylyx’s ongoing efforts in advancing its research and development initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.